United Therapeutics (NASDAQ:UTHR) Price Target Raised to $725.00

United Therapeutics (NASDAQ:UTHR) had its price objective hoisted by Leerink Partners from $685.00 to $725.00 in a research note issued to investors on Monday morning,Benzinga reports. Leerink Partners currently has an outperform rating on the biotechnology company’s stock.

UTHR has been the subject of a number of other research reports. Royal Bank Of Canada boosted their target price on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $368.00 price target on shares of United Therapeutics in a report on Thursday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of United Therapeutics in a research note on Thursday, October 1st. Finally, UBS Group set a $725.00 price target on shares of United Therapeutics in a research note on Monday. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $651.21.

United Therapeutics Price Performance

UTHR stock opened at $563.49 on Monday. United Therapeutics has a 1-year low of $409.07 and a 1-year high of $609.35. The business has a fifty day moving average price of $515.71 and a 200-day moving average price of $539.59. The stock has a market capitalization of $24.17 billion, a P/E ratio of 20.16, a P/E/G ratio of 3.96 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same period in the prior year, the company posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics will post 26.40 earnings per share for the current year.

Insider Transactions at United Therapeutics

In related news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $516.06, for a total transaction of $4,902,570.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $167,432,054.58. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 401,528 shares of company stock valued at $208,069,526 over the last 90 days. Company insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Arjuna Capital raised its stake in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after buying an additional 18 shares during the period. Sage Rhino Capital LLC grew its stake in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC grew its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the period. Meeder Advisory Services Inc. grew its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 26 shares during the period. Finally, Kera Capital Partners Inc. increased its holdings in United Therapeutics by 6.1% in the 1st quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts raised their outlook. Leerink Partners increased its price target for United Therapeutics to $725 from $685 while maintaining an “outperform” rating. The broader analyst consensus remains bullish, with a “Moderate Buy” rating and an average target near $650, implying further potential upside. Leerink Partners Raises Price Target
• Positive Sentiment: United Therapeutics expanded its xenograft capacity. The company opened its third designated pathogen-free xenograft production facility in Houston, Texas. The facility supports its longer-term strategy of developing genetically modified organs for transplantation and may strengthen future growth opportunities beyond its pulmonary hypertension drug franchise. Third Xenograft Production Facility
• Neutral Sentiment: Third-quarter earnings are approaching. United Therapeutics will report financial results before the market opens on November 4. The release could provide an important update on demand for Tyvaso and other pulmonary hypertension treatments, margins, and progress in organ manufacturing. Third-Quarter 2026 Earnings Announcement
• Negative Sentiment: Insider selling presents a modest cautionary signal. CEO Martine Rothblatt reported sales of 9,500 shares in transactions dated October 16 and October 19, reducing her position by about 2.84% in each filing. The company’s general counsel also sold shares under a trading plan. Because the sales appear relatively small compared with Rothblatt’s remaining stake and were conducted under planned arrangements, they do not necessarily indicate deteriorating business prospects.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.